Sign in with your email address username.


[Comment] PD-L1 in non-small-cell lung cancer: the third target for immunotherapy

Advanced-stage non-small-cell lung cancer (NSCLC) has a dismal prognosis. At disease presentation, more than 50% of patients have metastatic disease and, despite advances in chemotherapy and targeted therapy, median overall survival is less than 1 year. For patients who progress on first-line standard therapies, docetaxel is the treatment of choice and is associated with a median survival of 7·5 months.1 With the emergence of immune checkpoint inhibitors, the prognosis for a fairly large proportion of patients might finally start to improve.